Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir

J Acquir Immune Defic Syndr. 2022 Dec 1;91(4):e9-e11. doi: 10.1097/QAI.0000000000003077.
No abstract available

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Emtricitabine / therapeutic use
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Lamivudine / therapeutic use
  • Pyridones / therapeutic use

Substances

  • Emtricitabine
  • bictegravir
  • Lamivudine
  • Heterocyclic Compounds, 3-Ring
  • Pyridones
  • Anti-HIV Agents